Drug Profile
Research programme: bispecific oncology antibodies - Light Chain Bioscience
Alternative Names: NI 1601Latest Information Update: 30 Dec 2022
Price :
$50
*
At a glance
- Originator NovImmune SA
- Developer Light Chain Bioscience
- Class Antineoplastics; Bispecific antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD19 antigen inhibitors; CD47 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 30 Dec 2022 Discontinued - Preclinical for Cancer in Switzerland (Parenteral)
- 28 Jun 2020 No recent reports of development identified for preclinical development in Cancer in Switzerland (Parenteral)
- 21 Apr 2018 Bispecific oncology antibodies are still in preclinical development for Cancer in Switzerland